Please wait...

You selected inventions in category Medicine

  • 'Angioplasty' Repair for GI tracts, Vascular Systems....  & Mechanical Plumbing Systems'Angioplasty' Repair for GI tracts, Vascular...
      Preview
      Description

      Medical Application:

      The overall catheter market in the U.S. alone is over 10 billion dollars¬ a year and growing. Featuring targeted treatment capability (not currently offered in the present state of the art), this elastomeric shell works by expanding first at both ends (in a barbell shape), which isolates the middle section for treatment. The medical version of this device can be used to isolate and treat a specific section in a blood vessel, GI tract, CNS tract, urinary tract, respiratory tract, etc. Because the targeted area can be isolated and treated, more potent and effective treatment regimens can be applied without endangering adjacent tissue, or patient. Furthermore, isolated section of blood vessel or GI/CNS/urinary/respiratory tract can be treated while using device's pass-through feature where needed, which can allow normal function while procedure is taking place—reducing potential complications. Device can also be used to install and then enhance the effectiveness of stents via supplemental coating of stent after installation. Device can also be used to isolate, dissolve, and actually remove clots and plaque in blood vessels. Device can also be used to seal/fortify perforations, e.g. Crohn’s disease or diverticulitis in GI tract, using suitable medicated sealants—precluding the need for more invasive surgery. Along the same line, it can be used to seal a failed surgical union in a GI resection, ~ 5,000 failures annually, avoiding the need for further surgeries including colostomy. Device can also be used to treat cancerous polyp sites, on or after removal, by isolating and treating site with potent anti-cancer drugs. Overall, this device is the perfect vehicle for delivering targeted treatment in GI, CNS, vascular, urinary, respiratory, and similar systems.

      Mechanical Application:

      A slab leak in the U.S. costs between $625-$4,400 to pin-point and repair. Prior state of the art does not isolate and quickly repair angled sections of pipe, let alone perform repair while plumbing still in use. Commercially perfected over the last 14 years for pool plumbing, this is THE state-of-the-art device and method for internally repairing pipes. The device consists of an elastomeric, bladder-like shell that first expands at both ends (in a barbell shape), which isolates the section in-between for repair. The design of the device itself aids in positioning the expandable shell over and helps seal off the leak area inside a pipe, including pipe elbows--crucial capabilities other methods do not address. Once inflated into proper position, a sealant is injected into the leak area. Not only does the sealant eventually seal and fortify inside the pipe it also forms a seal around the outside of the pipe. Once the sealant has cured, the device is deflated and removed from the pipe--usually within 30 minutes after application. Besides working in angled sections of pipe, minimal pipe preparation and a quick return to operational capacity are other standout features of this device. Finally, the elastomeric shell can be configured with a pass-through opening to enable repair of plumbing actively in use, which can eliminate the need for costly down time.

      Full details Contact close
    • A Cheap Cure For Obesity and Blood Sugar ProblemsA Cheap Cure For Obesity and Blood Sugar Problems
        Preview
        Description

        A cheaper cure for Type II diabetes and to reduce obesity effeciently. The American Diabetes Association recognises an operation called the Roux en y as a cure for 87% of Type II diabetes. Another operation called the gastric sleeve has the same effect of both curing Type II and also reducing obesity, as the roux en y was originally designed. It's believed the cause of diabetes is the irritation of the duodenim, the tube between the stomach and upper gi. The sleeve operation has the same effects as the roux en y; the hormones start to convert to normal in about a week, and it's believed the weight loss involved also is related to the hormones since insulin is the main fat storage hormone. The roux en y is out of reach of most with diabetes due to its higher risk than the duodenum operation which is less invasive. But the duodenal sleeve operation costs about three thousand dollars. My invention is a small cheap robot pill, that works by changing the duodenum. The pill is biodegradable so it's completely safe, and a 20 dollar OTC that may cure both Type II and obesity.

        Art Orbiting Candy Copyright 2013 By charles L

        Full details Contact close
      • A Formulation for treating LeishmaniasisA Formulation for treating Leishmaniasis
          Preview
          Description

          The technology is in form of a formulation that is effective in treating intracellular protozoan parasitic infections (especially Leishmaniasis) and overcoming the associated complications. The technology provides a sterol enriched mixed lamellarity amphotericin intercalating liposomes for targeted delivery of liposomal amphotericin B thereby reducing toxicities of amphotericin B. The liposomal formulation is sonicated before administration to increase the plasma half-life of the liposomal drug for facilitating better bio-distribution in the body. The formulation is sugar free and thus can be freely use by diabetics. The technology has been tested on the mice for tolerance study

          Full details Contact close
        • A herbal pesticideA herbal pesticide
            Preview
            Description

            The present technology provides a sprayable biopesticidal composition comprising Photorhabdus luminescens for controlling and eradicating various agricultural pests. It is for the first time that the insecticidal activity of P. luminescens is used without its symbiotic carrier nematode. In the present technology the actively growing cells of P. luminescens are encapsulated in sodium alginate beads and examined for their ability to infect insect hosts. Several laboratory and field testing programme were carried out to evaluate and assess the product. Elaborative and extensive field trials were conducted to study the efficacy of the product on the serious pest of sugarcane. The results obtained from these experiments have given a clear indication that the product is very effective and is novel based on the bacterium Photorhabdus luminescence and the plant, bacterial and insect chitinase purified to greatest extent and stabilized for longer shelf life.

            Full details Contact close
          • A kit to diagnose Heart diseaseA kit to diagnose Heart disease
              Preview
              Description

              The proposed technology suggests a heart disease diagnostics kit that uses multifractal analysis tests to produce an integrated, noninvasive diagnostic/prognostic approach for diagnosis of heart disease, prognostication, prediction of risk of sudden death, and prediction of response to therapy. Useful results from these tests can be made available in 15 minutes or less to several hours. A multifractal version of the ST alpha scaling coefficient and a multifractal version of the LT alpha offer additional useful information about cardiac disease. Researchers have also refined preexisting multifractal analytic methods to eliminate the confounding effect of skipped/abnormal/ectopic beats, frequently found in the general population and patients with cardiac disease.

              Full details Contact close
            • A Lipid-based Drug for Treating CancerA Lipid-based Drug for Treating Cancer
                Preview
                Description

                The technology is in form of a “Lipid based drug” which is aimed at treating cancer by occluding the blood supply to the tumor region. The said drug when injected intra-tumorally cut off the blood supply to the tumor, causing it to basically starve and die because of a lack of blood, without leaving any side-effect on the patient body. This is for the first time ever a lipid-based drug is developed for cancer. The molecule developed is a naturally occurring lipid present in the body, is non –toxic, and has both direct and selective tumoricidal and anti-angiogenic actions.
                The angiography study performed on five patients who have been administered this drug clearly highlights its highly selective mode of action. The administered drug selectively occludes tumor-feeding vessels without having any significant side-effects on the adjoining tissues.
                The methods of administration of this drug:
                (a) To locate an artery which carries major blood supply to the neoplastic region and which is proximal to the neoplastic region
                (b) Intra-arterially injection of therapeutically effective amount of “Lipid-based drug” into the located artery

                Full details Contact close
              • A NEW DRUG FOR THE PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRUS HSV-1A NEW DRUG FOR THE PREVENTION AND TREATMENT OF...
                  Preview
                  Description

                  Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.

                  Currently, there are several antiviral drugs, which are active against pathogens belonging to the Herpesviridae family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.

                  The main advantages of the offered drug are:
                   confirmed ability to efficient bind of herpes simplex virus (HSV-1)
                  and inhibit its replication in vitro,
                   low-toxicity of the drug in vitro,
                   the possibility to apply as an ointment or solution administrated either topically to the skin or eye, orally, intraperitoneally or intravenously.

                  The offered invention is subject of a patent application. Further research
                  and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for partners interested in the development of the invention and its commercial application.

                  More information:
                  PhD Klaudia Polakowska – Technology Transfer Officer
                  phone. +48 12 663 3832, +48 519 329 129, klaudia.polakowska@uj.edu.pl

                  Full details Contact close
                • A new drug for the prevention and treatment of human influenza A virus IAV human metapneumovirus hMPV and human rhinoviruses HRVA new drug for the prevention and treatment of...
                    Preview
                    Description

                    Potential drug: a modified polyallylamine derivative

                    Application: prevention and treatment of human influenza A virus (IAV), human metapneumovirus (hMPV) and human rhinoviruses (HRV)

                    Influenza is an acute infectious disease caused by viruses belonging to the Orthomyxoviridae family, and classified into three types: A, B and C. This classification is based on antigenic differences between the major virion proteins, e.g. M protein and nucleoprotein NP. These types differ in terms of epidemiological properties.

                    Influenza A virus (IAV) causes acute and chronic respiratory infections. It is a major respiratory pathogen of humans and animals. A period of frequent influenza infections occurs each winter (seasonal flu, the highest incidence occurring
                    in January/February). Only type A influenza virus causes epidemics and pandemics because of antigenic shift that is multiple changes in the various genome segments resulting from reassortment of different strains of the virus.

                    According to the World Health Organization (WHO) infections with influenza
                    and influenza-like viruses occur globally with an annual attack rate estimated at 5%-10% in adults and 20%-30% in children. Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths. The most severe infections develop in children under two years of age, in the elderly aged 65 or older and in those with compromised immunity. WHO recommends vaccination against the influenza virus as the most effective way to prevent infections. On the other hand, because of a large variability of the virus, the difficulty in obtaining sufficient number of vaccines before the epidemic wave, and not always satisfactory efficacy of the vaccine and anti – influenza drugs, the disease still represents an important medical and epidemiological problem. Therefore, new effective drugs for the anti-influenza treatment are needed.

                    The new invention of the Jagiellonian University, which is the subject
                    of the proposed offer, discloses a new drug for the treatment of human A virus (IAV) infection.

                    Human metapneumovirus (hMPV) was identified in 2001, however, it was proved that infections with this pathogen have occurred in the human population for
                    at least 50 years now. It is the only known Pneumovirus which infects humans and causes both upper and lower respiratory tract infections. Respiratory infections caused by hMPV have been reported in patients of every age and gender,
                    but children under 5 years are most likely to be susceptible to infections caused
                    by hMPV. The clinical manifestations of hMPV disease are flu-like symptoms such
                    as runny nose, cough, sore throat and high fever. The virus is widespread, and is found on all continents. Late winter and early spring is the epidemic peak of hMPV infections. More serious symptoms, including severe lower respiratory tract infections, are found mainly in young children and infants under 5 years
                    of age, elderly individuals above 60 years of age, and immunocompromised patients, whereas immunocompetent adults present mostly flu-like illnesses or cold symptoms.
                    So far, no other drug has been approved for inhibition and prevention
                    of infections caused by hMPV. By 2012, the only drugs with broad spectrum
                    of activity (such as ribavirin and immunoglobulins) have been used to treat very acute, severe hMPV infections of patients after lung transplantation. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of human metapneumovirus (hMPV) infection.

                    The human rhinovirus (HRV) belongs to the smallest known viruses (their diameter does not exceed 30 nm). During the year, particularly in winter and spring, it causes infections of the upper respiratory tract with humans, appearing as the common cold. Rhinoviruses also cause otitis media, sinusitis and inflammations of the lower respiratory tract, including bronchi

                    Full details Contact close